Showing results (551-560 of 1,188) with videos related to

Sort By:
Pageof 119
Plos One|August 27, 2013
Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromesSophie Dimicoli, Yue Wei, Carlos Bueso-Ramos, et al.
Cancer|October 6, 2018
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutionsDavid P Steensma, Andrew M Brunner, Amy E DeZern, et al.
American Journal of Infection Control|August 9, 2016
Control of an outbreak of postoperative bone mucormycosis: An intervention study of contiguous cohortsMarcelo S Chaves, Diego Franco, Juan C Nanni, et al.
Molecular Vision|May 6, 2020
Clinical, histopathological, and in silico pathogenicity analyses in a pedigree with familial amyloidosis of the Finnish type (Meretoja syndrome) caused by a novel gelsolin mutationJesus Cabral-Macias, Leopoldo A Garcia-Montaño, Mario Pérezpeña-Díazconti, et al.
Blood|October 24, 2002
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
British Journal of Haematology|November 10, 2009
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)Gheath Alatrash, Maher Albitar, Susan O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2017
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive LeukemiaRita Assi, Hagop Kantarjian, Nicholas J Short, et al.
Cancer Medicine|December 22, 2020
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research ConsortiumRami S Komrokji, Najla H Al Ali, David Sallman, et al.
Leukemia & Lymphoma|February 19, 2019
A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failureMahesh Swaminathan, Gautam Borthakur, Tapan M Kadia, et al.
Cancer|January 19, 2012
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score systemWei-Gang Tong, Alfonso Quintás-Cardama, Tapan Kadia, et al.
Pageof 119